SCHEMBL5545257

SCHEMBL5545257

O=[C]OC(c1ccc(Cl)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.46
TDO2 P48775 4/20 0.46
IDO2 Q6ZQW0 1/20 0.46
TP53 P04637 1/20 0.39
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 1/20 0.38
EPHX1 P07099 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
CHRM1 P11229 1/20 0.38
SLC6A2 P23975 1/20 0.38
PDE4A P27815 1/20 0.38
EPHX2 P34913 1/20 0.38
ADRA1A P35348 1/20 0.38
OPRM1 P35372 1/20 0.38
HTT P42858 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE3A Q14432 1/20 0.38
NLRP3 Q96P20 1/20 0.38
MDM2 Q00987 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542500 0.93 IDO1 (0.47) IDO1TDO2IDO2TP53MEN1
SCHEMBL5546047 0.87 IDO1 (0.50) IDO1TDO2TP53LMNAMAPK1
SCHEMBL5545317 0.81 IDO1 (0.43) IDO1TDO2IDO2MEN1OPRM1
SCHEMBL5537747 0.80 IDO1 (0.58) IDO1TDO2IDO2TP53MEN1
SCHEMBL5545262 0.76 IDO1 (0.46) IDO1TDO2IDO2TP53MEN1
SCHEMBL5544361 0.73 ACP3 (0.42) IDO1TDO2MEN1LMNAHTT
SCHEMBL5545080 0.72 ACP3 (0.46) IDO1TDO2IDO2MEN1NPC1
SCHEMBL5545005 0.71 IDO1 (0.41) IDO1TDO2
SCHEMBL5541129 0.71 CES2 (0.41)
SCHEMBL5536361 0.69 IDO1 (0.47) IDO1TDO2TP53MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IDO1 3181/4885TDO2 1351/4885IDO2 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.